Patient-Reported Outcome Of Facial Erythema (PROOF)

Overview

The purpose of the study is to evaluate the patient-reported outcomes (feedbacks of patients)of a new drug for the treatment of erythema of rosacea (central facial redness). The feedback of patients receiving the active drug will be compared to the feedback of patients receiving the placebo.

Full Title of Study: “Patient-Reported Outcomes of Brimonidine Tartrate 0.5% Gel for Treatment of Severe Facial Erythema of Rosacea”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: November 14, 2013

Interventions

  • Drug: Brimonidine tartrate was applied cutaneously once daily for 8 days.
  • Drug: Brimonidine tartrate vehicle was applied cutaneously once daily for 8 days.

Arms, Groups and Cohorts

  • Experimental: Brimonidine tartrate 0.5% gel
    • Participants applied brimonidine tartrate 0.5% gel topically once daily for 8 days.
  • Placebo Comparator: Vehicle
    • Participants applied brimonidine tartrate vehicle gel topically once daily for 8 days.

Clinical Trial Outcome Measures

Primary Measures

  • Percentage of Participants Who Are Very Satisfied/Satisfied/Somewhat Satisfied With the Overall Study Treatment
    • Time Frame: Day 8
    • Percentage of participants who are very satisfied/satisfied/somewhat satisfied with the study treatment were reported.
  • Percentage of Participants With Facial Redness Questionnaire at Day 8
    • Time Frame: Day 8
    • Percentage of participants for each category of facial redness questionnaire on Day 8 was reported. Facial redness questionnaire included 12 questions/categories 1. Satisfied with appearance, 2. Appearance acceptable, 3. Appearance concerned, 4. Embarrassed with facial redness, 5. Self-conscious, 6. Frequency control last 24 hours, 7. Frustrated, 8. Cover up or camouflage, 9. Pay attention to the known triggers, 10. Avoid the known triggers, 11. Interfering with social life, 12. Interfering with work life.
  • EuroQuality of Life-5 Dimensional-3 Level (EQ-5D-3L) Questionnaire at Day 8
    • Time Frame: Day 8
    • EQ-5D-3L is a 3-level, 5-dimensional format standardized instrument for use as a measure of health outcome used to assess the impact of study treatments on participants quality of life as follows: 1) mobility; 2) self-care; 3) usual activities; 4) pain/discomfort; 5) anxiety/depression. Each dimension comprises 3 levels with corresponding numeric scores, where 1 indicates no problems, and 3 indicates extreme problems. Participant selects answer for each of 5 dimensions considering response that best matches his/her health today with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). An increase in the EQ-5D-3L total score indicates improvement.
  • Percent Change From Baseline in Total Score of Dermatology Life Quality Index (DLQI) Questionnaire at Day 8
    • Time Frame: Baseline, Day 8
    • DLQI was a compact health-related quality of life index that has 10 questions and depends on the participants self-declaration about experiences during the previous week. DLQI results range between grades 0 and 30. [Grade 0-1]: No effect at all on participant’s life, [Grade 2-5]: Small effect at all on participant’s life, [Grade 6-10]: Moderate effect at all on participant’s life, [Grade 11-20]: Very large effect at all on participant’s life, [Grade 21-30]: Extremely large effect at all on participant’s life. As the DLQI scores increase, the impact of the studied disease on life becomes greater.
  • Euro Quality of Life-5 Dimensional-3 Level (EQ-5D-3L) Questionnaire (Along With a Visual Analogue Score for the Overall Health State) at Day 8
    • Time Frame: Day 8
    • EQ-5D-3L is a 3-level, 5-dimensional format standardized instrument for use as a measure of health outcome used to assess the impact of study treatments on participants quality of life as follows: 1) mobility; 2) self-care; 3) usual activities; 4) pain/discomfort; 5) anxiety/depression. Each dimension comprises 3 levels with corresponding numeric scores, where 1 indicates no problems, and 3 indicates extreme problems. Participant selects answer for each of 5 dimensions considering response that best matches his/her health today with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). An increase in the EQ-5D-3L total score indicates improvement.

Secondary Measures

  • Percentage of Participants With at Least Two Grade Improvement in the Clinician’s Erythema Assessment (CEA)
    • Time Frame: Day 8
    • Evaluation of erythema by using CEA was assessed by 0 to 4 grades, where 0-Clear skin with no signs of erythema, 1- Almost clear; slight redness, 2-Mild erythema; definite redness, 3-Moderate erythema; marked redness, 4-Severe erythema; fiery redness. Percentage of participants with at least two grade improvement in the CEA was reported.
  • Percentage of Participants With at Least Two Grade Improvement in the Participant Self-assessment
    • Time Frame: Day 8
    • Percentage of participants with at least two grade improvement in the PSA was reported. Evaluation of erythema severity by using the PSA grades (0-4): 0- No redness, 1- very mild redness, 2-mild redness, 3-moderate redness, 4-severe redness.
  • Change From Baseline in Facial Inflammatory Lesion Counts at Day 8
    • Time Frame: Day 8
    • Facial inflammatory lesions of rosacea (including papules and pustules) were counted by evaluator.
  • Number of Participants Reported Adverse Events
    • Time Frame: From start of study drug administration up to Day 8
    • All clinical medical events, whether observed by the investigator or reported by the participant and whether or not thought to be product- or study procedure-related were considered as adverse events.

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female subjects age of 18 years or older – A clinical diagnosis of facial rosacea – A Patient Self-Assessment score of 4 (severe) at Baseline prior to the study drug application – A Clinician's Erythema Assessment (CEA) score of 3 (moderate) or 4 (severe) at Baseline prior to the study drug application Exclusion Criteria:

  • More than 5 facial inflammatory lesions (papules or pustules) of rosacea – Any uncontrolled chronic or serious disease or medical condition that may either interfere with the interpretation of the clinical trial results, or put the subject at significant risk if the subject participates in the clinical trial as judged by the investigator – Known or suspected allergies or sensitivities to any component of the study drugs, including the active ingredient brimonidine tartrate (see Investigator's Brochure) – Female who is pregnant or lactating

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Galderma R&D
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.